Cells were co-stained with FAM-FLICA and propidium iodide, stained with each reagent individually or left unstained
The CagriSema program, combining cagrilintide with semaglutide, has demonstrated: 15.1% mean body weight reduction at 32 weeks in REDEFINE 1 trial Approximately 15-17% weight loss in various phase 3 timepoints Superior outcomes compared to semaglutide monotherapy Manageable safety profile with expected GI side effects Cagrilintide 10mg remains an important research tool for scientists exploring amylin analogue applications
It interacts with receptors involved in stress response, circadian regulation, and sleep-wake cycling
Other GLP-1 and dual-agonist agents, including tirzepatide, are also in wide use, though not every GLP-1 on the market carries an FDA weight loss indication
DOI:10.1046/j.1523-1747.1998.00357.x [ Links ] 74
Transfer to a dark glass bottle and store in the refrigerator